VEGFA and neoplasm: In fact, it was shown in 2009 that although angiogenic inhibitors targeting the VEGF pathway block tumor growth in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma, they concomitantly elicit tumor adaptation and progression toward higher malignancy grade (Paez‐Ribes et al., 2009), which was evident by increased lymphatic and distant metastasis.